

# ESMO Preceptorship on Breast Cancer

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**SINGAPORE  
4-5 DECEMBER 2024**

**Co-Chairs**

Rebecca A. Dent, Singapore  
Matteo Lambertini, Italy

# ESMO PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets  
and future perspectives

Singapore  
4-5 December 2024

---

## CO-CHAIRS

Rebecca A. Dent, Singapore  
Matteo Lambertini, Italy

## SPEAKERS

Belinda E. Kiely, Australia  
Hee Jeong Kim, Republic of Korea  
Icro Meattini, Italy  
Soo Chin Lee, Singapore

Lester C. H. Leong, Singapore  
Kevin Punie, Belgium  
Tira J. Y. Tan, Singapore

---

## LEARNING OBJECTIVES

- To learn about screening, diagnosis and staging of breast cancer
- To learn about genetic testing and management of BRCA carriers
- To learn about the biology of breast cancer and its implications in the management of this disease
- To learn about the standard of care, management of early, locally advanced, and metastatic breast cancer in surgery, radiation therapy and systemic therapy
- To understand the crucial role of multidisciplinary care in the management of breast cancer

---

## ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by:



GILEAD

---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano, Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 4 December 2024

<b>09:00-09:10</b> 10'	<b>Opening and welcome</b>	
10'	Welcome and introduction	Rebecca A. Dent, SG Matteo Lambertini, IT
<b>09:10-09:55</b> 45'	<b>MODULE 1</b> <b>Imaging</b>	<b>Chair:</b> <b>Matteo Lambertini, IT</b>
30'	Imaging (diagnosis, staging, high-risk breast cancer, Artificial Intelligence)	Lester C. H. Leong, SG
15'	Q&A	All
<b>09:55-10:50</b> 55'	<b>MODULE 2</b> <b>Biology</b>	<b>Chair:</b> <b>Rebecca A. Dent, SG</b>
25'	New breast cancer classification and new technologies: What's relevant in everyday practice? (including Next Generation Sequencing and ESCAT scale)	Kevin Punie, BE
20'	Use of Genomic Assays in early breast cancer (ie. Oncotype, mammoprint etc..)	Kevin Punie, BE
10'	Q&A	All
<b>10:50-11:20</b>	<b>Coffee break</b>	
<b>11:20-12:55</b> 95'	<b>MODULE 3</b> <b>HER2+ Breast Cancer</b>	<b>Chair:</b> <b>Matteo Lambertini, IT</b>
25'	Escalation and de-escalation in (neo)-adjuvant systemic therapy: What is proven?	Tira J. Y. Tan, SG
25'	Systemic therapy for HER2+ advanced breast cancer: Now and in future	Matteo Lambertini, IT
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
<b>12:55-13:55</b>	<b>Lunch</b>	
<b>13:55-15:20</b> 85'	<b>MODULE 4</b> <b>Triple Negative Breast Cancer (TNBC)</b>	<b>Chairs:</b> <b>Tira J. Y. Tan, SG</b>
20'	What is the optimal therapy in stage I, II, III in pCR and non-pCR?	Rebecca A. Dent, SG
20'	Systemic therapy for metastatic TNBC	Tira J. Y. Tan, SG
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
<b>15:20-15:50</b>	<b>Coffee break</b>	
<b>15:50-16:25</b> 35'	<b>MODULE 5</b> <b>Special patient population</b>	<b>Chair:</b> <b>Matteo Lambertini, IT</b>
25'	Special issues in treatment of elderly patients	Belinda E. Kiely, AU
10'	Q&A	All

<b>16:25-17:55</b> 90'	<b>MODULE 6</b> <b>Communicating bad news to cancer patients</b>	<b>Chair:</b> <b>Belinda E. Kiely, AU</b>
30'	Communicating bad news to cancer patients	Belinda E. Kiely, AU
10'	Q&A	All
50'	Participants clinical case discussion (5x10')	Faculty
<b>19:00</b>	<b>Networking dinner</b>	

## Thursday, 5 December 2024

<b>09:00-10:05</b> 65'	<b>MODULE 7</b> <b>Local-regional treatment</b>	<b>Chair:</b> <b>Icro Meattini, IT</b>
25'	Surgery: What strategy is safe for breast and axilla?	Hee Jeong Kim, KR
25'	Radiotherapy: How short is enough?	Icro Meattini, IT
15'	Q&A	All
<b>10:05-10:50</b> 45'	<b>MODULE 8</b> <b>Issues in Advanced Breast Cancer</b>	<b>Chair:</b> <b>Rebecca A. Dent, SG</b>
30'	ER+ Advanced Breast Cancer, 1 <sup>st</sup> line and beyond (PIK3CA, ESR1 mutations, ADCs, AKT, etc...)	Soo Chin Lee, SG
15'	Q&A	All
<b>10:50-11:20</b>	<b>Coffee break</b>	
<b>11:20-11:55</b> 35'	<b>MODULE 9</b> <b>BRCA</b>	<b>Chair:</b> <b>Rebecca A. Dent, SG</b>
20'	Genetic counselling/testing and its therapeutic implications	Soo Chin Lee, SG
15'	Q&A	All
<b>11:55-13:10</b> 75'	<b>MODULE 10</b> <b>Early ER+ Breast Cancer</b>	<b>Chair:</b> <b>Hee Jeong Kim, KR</b>
20'	Pregnancy: Planning for, during and after treatment	Matteo Lambertini, IT
20'	Systemic therapy for adjuvant ER+ and when is ovarian suppression warranted?	Hee Jeong Kim, KR
20'	Best systemic therapy high risk ER+ HER2 negative breast cancer? (choice of chemo, role of CDKi)	Icro Meattini, IT
15'	Q&A	All
<b>13:10-13:15</b> 5'	<b>Closing remarks</b>	<b>Rebecca A. Dent, SG</b> <b>Matteo Lambertini, IT</b>
<b>13:15-14:15</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion